Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of lab testing services specialist Bio-Reference Laboratories
So what: Driven by a solid 25% increase in revenue, Bio-Reference posted second-quarter earnings of $0.26 per share, versus the average analyst estimate of $0.24 per share. If your initial reaction is that a $0.02 earnings beat doesn't exactly justify a double-digit price rally, Mr. Market has already come around to your way of thinking. Since the opening spike, the shares have quickly sold off and are now up only 2.4% at the time of this writing.
Now what: I'd take this midday price weakness as a tempting buy-in point. Given the strong operating momentum (patients serviced increased 25%, as well) and demographic tailwinds working in its favor, Bio-Reference seems like a good bet to keep delivering solid top- and bottom-line growth in the foreseeable future. More importantly, with a PEG ratio in line with larger rivals LabCorp
Interested in more info on Bio-Reference? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Bio-Reference. Motley Fool newsletter services have recommended buying shares of LabCorp and Quest. Try any of our Foolish newsletter services free for 30 days.